Purchase FUB-AMB
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy FUB-AMB for sale
FUB-AMB (also known as MMB-FUBINACA) is an indazole-based synthetic cannabinoid that Pfizer originally developed; it described the compound in a patent in 2009 but was later abandoned and never tested on humans. It is a potent agonist for cannabinoid receptors and has been sold online as a designer drug. FUB-AMB was the most common synthetic cannabinoid identified in drug seizures by the Drug Enforcement Administration in 2017 and the first half of 2018.
FUB-AMB is an indazole-based synthetic cannabinoid that Pfizer originally developed in 2009 and has been sold online as a designer drug. It is a potent agonist for cannabinoid receptors.
FUB-AMB is a synthetic cannabinoid classified as an indazole-based, potent CB1 receptor agonist. It has been sold online as a designer drug.
FUB-AMB is a synthetic cannabinoid that can be classified as a designer drug.
The FDA has warned consumers not to use five drugs that Pfizer developed but never tested in humans.
FUB-AMB (also known as MMB-FUBINACA) is a potent agonist for cannabinoid receptors. Pfizer first developed it, but it was abandoned and never tested on humans. The United States Drug Enforcement Administration has identified FUB-AMB as one of the most common synthetic cannabinoids identified in drug seizures since 2017.
FUB-AMB (also known as MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist for cannabinoid receptors. It was originally developed by Pfizer, describing the compound in a patent in 2009, but it was later abandoned and never tested on humans.
FUB-AMB (MMB-FUBINACA) is an indazole-based synthetic cannabinoid that was first discovered in 2011 and was described in a scientific publication about its synthesis and receptor binding profile.
FUB-AMB (MMB-FUBINACA) is an indazole cannabinoid that was discovered in 2009. It is a potent agonist of both the CB1 and CB2 receptors with an EC50 of 0.34nM at CB1 and 0.87nM at CB2.
FUB-AMB, or MMB-FUBINACA, is a cannabinoid used as an active ingredient in synthetic cannabis products.
FUB-AMB (MMB-FUBINACA) is an antagonist for the cannabinoid receptors that compete with THC and has sedative, analgesic, muscle relaxant, neurochemical and anti-inflammatory properties.
FUB-AMB has been utilized in scientific research as an agonist.
FUB-AMB is an indazole-based synthetic cannabinoid that is a potent agonist for cannabinoid receptors and has been sold online as a designer drug. FUB-AMB is a schedule I controlled substance in the United States.
FUB-AMB (1-(4-fluorobenzyl)-1H-indole-3-carboxylic acid, is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors and has been sold online as a designer drug. FUB-AMB is a schedule I controlled substance in the United States.
FUB-AMB(5-fluorophenyl-(indazole-3-carboxamide) is a new synthetic cannabinoid designer drug structurally similar to a series of commonly abused synthetic cannabinoids.
FUB-AMB is known for its psychoactive effects. It also has a detectable amount of naphthalene when tested.
FUB-AMB is a potent synthetic cannabinoid developed by Pfizer, and its structure differs very little from the active ingredient in cannabis. It is thought to be highly addictive and has killed users worldwide while causing severe long-term damage to others.
FUB-AMB is a synthetic cannabinoid developed by Pfizer, and its structure differs very little from the active ingredient in cannabis.
FUB-AMB, manufactured by Pfizer, was a synthetic cannabinoid developed after they studied the potent active ingredient in cannabis. Used for pain management, it resulted in addiction, death, and long-term damage to its victims.
FUB-AMB is classified as a synthetic cannabinoid and is thought to be highly addictive, and has caused severe, long-term damage to users worldwide.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics